{"id":"topical-dapsone-5-gel","safety":{"commonSideEffects":[{"rate":null,"effect":"Local skin irritation"},{"rate":null,"effect":"Erythema"},{"rate":null,"effect":"Dryness"},{"rate":null,"effect":"Contact dermatitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dapsone is a sulfone antimicrobial agent that inhibits bacterial folate synthesis and possesses immunomodulatory effects that reduce neutrophilic inflammation. When formulated as a topical 5% gel, it delivers the drug directly to affected skin areas, minimizing systemic exposure while treating localized inflammatory and infectious skin conditions.","oneSentence":"Topical dapsone reduces inflammation and bacterial colonization in skin lesions through its antimicrobial and anti-inflammatory properties.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:54:20.053Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acne vulgaris"},{"name":"Rosacea"},{"name":"Other inflammatory skin conditions"}]},"trialDetails":[{"nctId":"NCT05926869","phase":"PHASE2","title":"Comparison of the Efficacy of Clindamycin Phosphate 1% Gel Versus Once-daily Dapsone 5% Gel in the Treatment of Moderate Acne Vulgaris","status":"COMPLETED","sponsor":"Jinnah Postgraduate Medical Centre","startDate":"2022-08-01","conditions":"Acne Vulgaris","enrollment":100},{"nctId":"NCT05899699","phase":"PHASE2","title":"Effect of New Topical Preparation for Treatment of Acne Vulgaris","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2023-06-05","conditions":"Acne Vulgaris","enrollment":20},{"nctId":"NCT01115244","phase":"PHASE4","title":"Use of Dapsone Gel, 5% for Treating Dermatitis Herpetiformis","status":"TERMINATED","sponsor":"Vanderbilt University Medical Center","startDate":"2010-07","conditions":"Dermatitis Herpetiformis","enrollment":1},{"nctId":"NCT00964366","phase":"PHASE4","title":"Study to Determine and Compare the Tolerance and Irritation Potential of Topical Acne Medications","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2009-07","conditions":"Acne Vulgaris","enrollment":53},{"nctId":"NCT02929719","phase":"PHASE1","title":"Study Comparing Test to Aczone 5% and Both to a Placebo Control in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2014-04","conditions":"Acne Vulgaris","enrollment":1134},{"nctId":"NCT01931150","phase":"PHASE3","title":"Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-08","conditions":"Cetuximab-induced Papulopustular (Acneiform) Rash Who Have, Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma","enrollment":11},{"nctId":"NCT02865005","phase":"PHASE3","title":"Trial of Dapsone 5.0% Gel in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Seegpharm S.A.","startDate":"2016-02","conditions":"Acne Vulgaris","enrollment":2361},{"nctId":"NCT01231334","phase":"PHASE4","title":"A Study Comparing Aczone® Plus Differin® Versus Duac® Plus Differin® in Patients With Severe Facial Acne","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-08","conditions":"Acne Vulgaris","enrollment":286},{"nctId":"NCT00834210","phase":"PHASE4","title":"Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris","status":"COMPLETED","sponsor":"Allergan","startDate":"2008-12","conditions":"Acne Vulgaris","enrollment":171},{"nctId":"NCT00835198","phase":"PHASE4","title":"Dapsone Gel 5% and Tretinoin Gel 0.025% Versus Tretinoin Gel 0.025% Monotherapy for Facial Acne Vulgaris","status":"COMPLETED","sponsor":"Allergan","startDate":"2008-12","conditions":"Acne Vulgaris","enrollment":163},{"nctId":"NCT00151541","phase":"PHASE3","title":"A Phase 3 Study to Compare the Safety and Efficacy of 5% Dapsone Topical Gel, (DTG) Twice Daily in Combination With Once Daily Vehicle Control, Adapalene Gel 0.1% or Benzoyl Peroxide Gel 4%","status":"COMPLETED","sponsor":"Allergan","startDate":"2005-02","conditions":"Acne Vulgaris","enrollment":301}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Topical Dapsone 5% Gel","genericName":"Topical Dapsone 5% Gel","companyName":"Memorial Sloan Kettering Cancer Center","companyId":"memorial-sloan-kettering-cancer-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Topical Dapsone 5% Gel is used to treat moderate Acne Vulgaris, as per the study \"Comparison of the Efficacy of Clindamycin Phosphate 1% Gel Versus Once-daily Dapsone 5% Gel in the Treatment of Moderate Acne Vulgaris\" (NCT05926869). Additionally, it has been studied for the treatment of Dermatitis Herpetiformis, Cetuximab-induced Papulopustular (Acneiform) Rash, Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma, but the efficacy in these conditions is not specified in the provided facts.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}